Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Actinogen Medical ( (AU:ACW) ) has issued an announcement.
Actinogen Medical is advancing its revolutionary oral therapeutic, Xanamem, through pivotal trials aimed at transforming the treatment landscape for Alzheimer’s disease and major depressive disorder. This advancement reflects the company’s commitment to improving lives through precision and innovation, potentially impacting its operations and industry positioning significantly.
More about Actinogen Medical
Actinogen Medical is a company in the pharmaceutical industry focused on developing innovative oral therapeutics. Their primary product, Xanamem, is aimed at transforming the treatment of Alzheimer’s disease and major depressive disorder by targeting brain cortisol.
Average Trading Volume: 2,554,642
Technical Sentiment Signal: Hold
Current Market Cap: A$98.44M
See more data about ACW stock on TipRanks’ Stock Analysis page.